BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 25205655)

  • 1. Novel selective estrogen mimics for the treatment of tamoxifen-resistant breast cancer.
    Molloy ME; White BE; Gherezghiher T; Michalsen BT; Xiong R; Patel H; Zhao H; Maximov PY; Jordan VC; Thatcher GR; Tonetti DA
    Mol Cancer Ther; 2014 Nov; 13(11):2515-26. PubMed ID: 25205655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extranuclear ERα is associated with regression of T47D PKCα-overexpressing, tamoxifen-resistant breast cancer.
    Perez White B; Molloy ME; Zhao H; Zhang Y; Tonetti DA
    Mol Cancer; 2013 May; 12():34. PubMed ID: 23634843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel antitumor effect of estradiol in athymic mice injected with a T47D breast cancer cell line overexpressing protein kinase Calpha.
    Chisamore MJ; Ahmed Y; Bentrem DJ; Jordan VC; Tonetti DA
    Clin Cancer Res; 2001 Oct; 7(10):3156-65. PubMed ID: 11595710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression of PKCalpha is required to impart estradiol inhibition and tamoxifen-resistance in a T47D human breast cancer tumor model.
    Lin X; Yu Y; Zhao H; Zhang Y; Manela J; Tonetti DA
    Carcinogenesis; 2006 Aug; 27(8):1538-46. PubMed ID: 16513679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of pigment epithelium-derived factor: a novel mechanism for the development of endocrine resistance in breast cancer.
    Jan R; Huang M; Lewis-Wambi J
    Breast Cancer Res; 2012 Nov; 14(6):R146. PubMed ID: 23151593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estradiol-induced regression in T47D:A18/PKCalpha tumors requires the estrogen receptor and interaction with the extracellular matrix.
    Zhang Y; Zhao H; Asztalos S; Chisamore M; Sitabkhan Y; Tonetti DA
    Mol Cancer Res; 2009 Apr; 7(4):498-510. PubMed ID: 19372579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor activity of Z-endoxifen in aromatase inhibitor-sensitive and aromatase inhibitor-resistant estrogen receptor-positive breast cancer.
    Jayaraman S; Hou X; Kuffel MJ; Suman VJ; Hoskin TL; Reinicke KE; Monroe DG; Kalari KR; Tang X; Zeldenrust MA; Cheng J; Bruinsma ES; Buhrow SA; McGovern RM; Safgren SL; Walden CA; Carter JM; Reid JM; Ingle JN; Ames MM; Hawse JR; Goetz MP
    Breast Cancer Res; 2020 May; 22(1):51. PubMed ID: 32430040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tamoxifen resistance alters sensitivity to 5-fluorouracil in a subset of estrogen receptor-positive breast cancer.
    Watanabe T; Oba T; Tanimoto K; Shibata T; Kamijo S; Ito KI
    PLoS One; 2021; 16(6):e0252822. PubMed ID: 34101751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the selective estrogen receptor modulator arzoxifene (LY353381) with tamoxifen on tumor growth and biomarker expression in an MCF-7 human breast cancer xenograft model.
    Detre S; Riddler S; Salter J; A'Hern R; Dowsett M; Johnston SR
    Cancer Res; 2003 Oct; 63(19):6516-22. PubMed ID: 14559845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Idoxifene antagonizes estradiol-dependent MCF-7 breast cancer xenograft growth through sustained induction of apoptosis.
    Johnston SR; Boeddinghaus IM; Riddler S; Haynes BP; Hardcastle IR; Rowlands M; Grimshaw R; Jarman M; Dowsett M
    Cancer Res; 1999 Aug; 59(15):3646-51. PubMed ID: 10446976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of cross-resistance of the selective estrogen receptor modulators arzoxifene (LY353381) and LY117018 in tamoxifen-stimulated breast cancer xenografts.
    Schafer JM; Lee ES; Dardes RC; Bentrem D; O'Regan RM; De Los Reyes A; Jordan VC
    Clin Cancer Res; 2001 Aug; 7(8):2505-12. PubMed ID: 11489833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid Induction of the Unfolded Protein Response and Apoptosis by Estrogen Mimic TTC-352 for the Treatment of Endocrine-Resistant Breast Cancer.
    Abderrahman B; Maximov PY; Curpan RF; Fanning SW; Hanspal JS; Fan P; Foulds CE; Chen Y; Malovannaya A; Jain A; Xiong R; Greene GL; Tonetti DA; Thatcher GRJ; Jordan VC
    Mol Cancer Ther; 2021 Jan; 20(1):11-25. PubMed ID: 33177154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metformin enhances tamoxifen-mediated tumor growth inhibition in ER-positive breast carcinoma.
    Ma J; Guo Y; Chen S; Zhong C; Xue Y; Zhang Y; Lai X; Wei Y; Yu S; Zhang J; Liu W
    BMC Cancer; 2014 Mar; 14():172. PubMed ID: 24612549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression.
    Raha P; Thomas S; Thurn KT; Park J; Munster PN
    Breast Cancer Res; 2015 Feb; 17(1):26. PubMed ID: 25848915
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GPR30 as an initiator of tamoxifen resistance in hormone-dependent breast cancer.
    Mo Z; Liu M; Yang F; Luo H; Li Z; Tu G; Yang G
    Breast Cancer Res; 2013 Nov; 15(6):R114. PubMed ID: 24289103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacology and Molecular Mechanisms of Clinically Relevant Estrogen Estetrol and Estrogen Mimic BMI-135 for the Treatment of Endocrine-Resistant Breast Cancer.
    Abderrahman B; Maximov PY; Curpan RF; Hanspal JS; Fan P; Xiong R; Tonetti DA; Thatcher GRJ; Jordan VC
    Mol Pharmacol; 2020 Oct; 98(4):364-381. PubMed ID: 32788222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reversal of tamoxifen resistant breast cancer by low dose estrogen therapy.
    Osipo C; Gajdos C; Cheng D; Jordan VC
    J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):249-56. PubMed ID: 15860267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hedgehog signaling is a novel therapeutic target in tamoxifen-resistant breast cancer aberrantly activated by PI3K/AKT pathway.
    Ramaswamy B; Lu Y; Teng KY; Nuovo G; Li X; Shapiro CL; Majumder S
    Cancer Res; 2012 Oct; 72(19):5048-59. PubMed ID: 22875023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of a receptor-negative, hormone-nonresponsive clone derived from a T47D human breast cancer cell line kept under estrogen-free conditions.
    Murphy CS; Pink JJ; Jordan VC
    Cancer Res; 1990 Nov; 50(22):7285-92. PubMed ID: 2224859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual targeting of EphA2 and ER restores tamoxifen sensitivity in ER/EphA2-positive breast cancer.
    Gökmen-Polar Y; Toroni RA; Hocevar BA; Badve S; Zhao Q; Shen C; Bruckheimer E; Kinch MS; Miller KD
    Breast Cancer Res Treat; 2011 Jun; 127(2):375-84. PubMed ID: 20602165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.